JSPR · Jasper Therapeutics, Inc.
$0.48
0.00 (-0.52%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, based on the Company's current operating plan, and along with the Company's history of operating losses, and given the potential risk of having to repurchase the Non-Voting Convertible Preferred Stock if the Company is unable to obtain stockholder approval to convert it to Common Stock within 12 months, the Company's current cash and cash equivalents may not be sufficient to fund the Company's ongoing operations for a period of at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$15.97M
Shares
33.27M
Volume · Oct 19
391.73K
Avg daily vol (3M)
564.32K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.48
Open$0.47
Day$0.46–0.49
52W close$0.34–2.54
Avg vol 30d356K
Short int6.2M · 18.7% float · 16.3d
Short vol38%
Last earningsJun 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$31.77M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$7.31M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+87.1%
Year over year · more shares
Price change (1Y)
-80.6%
Trailing year
Short interest
18.7%
Latest settlement · 16.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−47%
below
Price vs 50-day avg
−27%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
6%
near low
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−49%
trailing
YTD return
−74%
this year
Relative strength
−56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 54 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
18.69% of float · ▲ +7.1% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
54 holders — mid 3-yr range
Squeeze score
80
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
104%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
12.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−47%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 54 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
18.69% of float · ▲ +7.1% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
54 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 6%
Range high $3
vs 200-day avg -47%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JSPR
this stock
Jasper Therapeutics, Inc.
|
$15.97M | -73.9% | — | — | 18.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +1.3% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JSPR | -14.0% | -20.8% | -48.7% | -17.7% | -73.9% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -12.5% | -19.9% | -56.4% | -18.2% | -86.3% |